Article
Relapse timing is associated with distinct evolutionary dynamics in DLBCL
2023-03-08
Abstract excerpt
Diffuse large B-cell lymphoma (DLBCL) is cured in over 60% of patients, but outcomes are poor for patients with relapsed or refractory disease (rrDLBCL). Here, we performed whole genome/exome sequencing (WGS/WES) on tumors from 73 serially-biopsied patients with rrDLBCL. Based on the observation that outcomes to salvage therapy/autologous stem cell transplantation are related to time-to-relapse, we stratified pati...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7c7749cc-5ff0-5427-8eb8-b4fcf72cd2bc
- DOI
- 10.1101/2023.03.06.23286584
